MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions

Published:2019-01 Issue: Volume:42 Page:1-11
ISSN:1368-7646
Container-title:Drug Resistance Updates
language:en
Short-container-title:Drug Resistance Updates

Author:

Leonetti Alessandro,Assaraf Yehuda G.,Veltsista Paraskevi D.,El Hassouni Btissame,Tiseo Marcello,Giovannetti Elisa

Funder

Italian Association for Cancer Research

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Cancer Research,Pharmacology,Oncology

Reference100 articles.

1. Cytoplasmic DNA innate immune pathways;Barber;Immunol. Rev.,2011

2. MicroRNA as tools and therapeutics in lung cancer;Barger;Respir. Med.,2015

3. EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations;Bastid;Cancer Metastasis Rev.,2012

4. Overview upon miR-21 in lung cancer: focus on NSCLC;Bica-Pop;Cell. Mol. Life Sci.,2018

5. Higher expression of MIR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients;Bisagni;PLoS One,2018

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. XAF1 overexpression inhibits the malignant progression and cisplatin resistance of NSCLC by activating endoplasmic reticulum stress;Molecular Biology Reports;2024-03-23

2. Synthesis, design, biological evaluation, and computational analysis of some novel uracil-azole derivatives as cytotoxic agents;BMC Chemistry;2024-01-03

3. Nanoenabled intracellular zinc bursting for efficacious reversal of gefitinib resistance in lung cancer;International Journal of Biological Sciences;2024

4. MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC;Journal of Thoracic Oncology;2023-11

5. Identification of associations between lncRNA and drug resistance based on deep learning and attention mechanism;Frontiers in Microbiology;2023-04-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3